Abstract
Introduction: Tumor exosome-derived miRNAs play important roles in the human laryngocarcinoma. However, it is still unknown if exosome miR-552 is involved in the laryngocarcinoma. The aim of the current study was to explore exosome miR-552’s role in laryngocarcinoma and its underlying mechanisms. Methods: Hep-2 exosome was characterized by transmission electron microscopy and nanoparticle tracking technology. CCK-8 was used to determine cell viability, and a xenograft animal model was used to determine the tumorigenicity. qPCR and Western blotting were used to measure the changes in target biomarkers. Luciferase reporter assay was used to evaluate the interactions between miR-552 and PTEN. miRNA sequencing was used to check the changes in miRNA profiles. Results: miR-552 was upregulated in the laryngocarcinoma patients and was positively correlated to the cell proliferation and tumor growth. PTEN was identified as a direct target of miR-552. Hep-2 exosome is featured by high expression of miR-552 and treatment of Hep-2 exosome enhanced cell proliferation and tumorigenicity. The underlying mechanisms revealed that treatment of exosomes enhanced the malignant transformation of recipient cells in part by regulating epithelial-mesenchymal transition. Conclusion: Exosome miR-552 promotes laryngocarcinoma cells’ malignant progression in part by the regulation of the PTEN/TOB1 axis.
References
1.
Obid
R
, Redlich
M
, Tomeh
C
. The treatment of laryngeal cancer
. Oral Maxillofac Surg Clin North Am
. 2019
;31
(1
):1
–11
.2.
Tomeh
C
, Holsinger
FC
. Laryngeal cancer
. Curr Opin Otolaryngol Head Neck Surg
. 2014
;22
(2
):147
–53
.3.
Chu
EA
, Kim
YJ
. Laryngeal cancer: diagnosis and preoperative work-up
. Otolaryngol Clin North Am
. 2008
;41
(4
):673
95, v
.4.
Stenson
KM
, Brockstein
BE
, Ross
ME
. Epidemiology and risk factors for head and neck cancer
. UpToDate
. 2014
.5.
Cattaruzza
MS
, Maisonneuve
P
, Boyle
P
. Epidemiology of laryngeal cancer
. Eur J Cancer B Oral Oncol
. 1996
32B
5
293
305
.6.
Clayman
GL
, Weber
RS
, Guillamondegui
O
, Byers
RM
, Wolf
PF
, Frankenthaler
RA
. Laryngeal preservation for advanced laryngeal and hypopharyngeal cancers
. Arch Otolaryngol Head Neck Surg
. 1995
;121
(2
):219
–23
.7.
Yu
X
, Li
Z
. The role of microRNAs expression in laryngeal cancer
. Oncotarget
. 2015
;6
(27
):23297
–305
.8.
Li
P
, Liu
H
, Wang
Z
, He
F
, Wang
H
, Shi
Z
. MicroRNAs in laryngeal cancer: implications for diagnosis, prognosis and therapy
. Am J Transl Res
. 2016
;8
(5
):1935
–44
.9.
Takeuchi
T
, Kawasaki
H
, Luce
A
, Cossu
AM
, Misso
G
, Scrima
M
. Insight toward the microRNA profiling of laryngeal cancers: biological role and clinical impact
. Int J Mol Sci
. 2020
;21
(10
):3693
.10.
Yu
X
, Wu
Y
, Liu
Y
, Deng
H
, Shen
Z
, Xiao
B
. miR-21, miR-106b and miR-375 as novel potential biomarkers for laryngeal squamous cell carcinoma
. Curr Pharm Biotechnol
. 2014
;15
(5
):503
–8
.11.
Xu
Y
, Wang
K
, Gao
W
, Zhang
C
, Huang
F
, Wen
S
. MicroRNA-106b regulates the tumor suppressor RUNX3 in laryngeal carcinoma cells
. FEBS Lett
. 2013
;587
(19
):3166
–74
.12.
Cai
K
, Wang
Y
, Bao
X
. MiR-106b promotes cell proliferation via targeting RB in laryngeal carcinoma
. J Exp Clin Cancer Res
. 2011
;30
(1
):73
–6
.13.
Li
X
, Wang
HL
, Peng
X
, Zhou
HF
, Wang
X
. miR-1297 mediates PTEN expression and contributes to cell progression in LSCC
. Biochem Biophys Res Commun
. 2012
;427
(2
):254
–60
.14.
Zou
Y
, Zhao
X
, Li
Y
, Duan
S
. miR-552: an important post-transcriptional regulator that affects human cancer
. J Cancer
. 2020
;11
(21
):6226
–33
.15.
Pegtel
DM
, Gould
SJ
. Exosomes
. Annu Rev Biochem
. 2019
;88
:487
–514
.16.
Théry
C
, Zitvogel
L
, Amigorena
S
. Exosomes: composition, biogenesis and function
. Nat Rev Immunol
. 2002
;2
(8
):569
–79
.17.
Kalluri
R
. The biology and function of exosomes in cancer
. J Clin Invest
. 2016
;126
(4
):1208
–15
.18.
Aryani
A
, Denecke
B
. Exosomes as a nanodelivery system: a key to the future of neuromedicine
. Mol Neurobiol
. 2016
;53
(2
):818
–34
.19.
Zhao
Q
, Zheng
X
, Guo
H
, Xue
X
, Zhang
Y
, Niu
M
. Serum Exosomal miR-941 as a promising oncogenic biomarker for laryngeal squamous cell carcinoma
. J Cancer
. 2020
;11
(18
):5329
–44
.20.
Dong
J
, Wang
J
, Shan
C
, Zhang
H
, Xu
O
. MicroRNA-892a regulates laryngocarcinoma cell proliferation via Dicer
. Exp Biol Med
. 2020
;245
(14
):1222
–32
.21.
He
G
, Pang
R
, Han
J
, Jia
J
, Ding
Z
, Bi
W
. TINCR inhibits the proliferation and invasion of laryngeal squamous cell carcinoma by regulating miR-210/BTG2
. BMC Cancer
. 2021
;21
(1
):753
–16
.22.
Gu
J
, Han
T
, Sun
L
, Yan
AH
, Jiang
XJ
. miR-552 promotes laryngocarcinoma cells proliferation and metastasis by targeting p53 pathway
. Cell Cycle
. 2020
;19
(9
):1012
–21
.23.
Lai
Y
, Dong
L
, Jin
H
, Li
H
, Sun
M
, Li
J
. Exosome long non-coding RNA SOX2-OT contributes to ovarian cancer malignant progression by miR-181b-5p/SCD1 signaling
. Aging
. 2021
;13
(20
):23726
–38
.24.
Yang
H
, Wang
J
, Fan
JH
, Zhang
YQ
, Zhao
JX
, Dai
XJ
. Ilexgenin A exerts anti-inflammation and anti-angiogenesis effects through inhibition of STAT3 and PI3K pathways and exhibits synergistic effects with Sorafenib on hepatoma growth
. Toxicol Appl Pharmacol
. 2017
;315
:90
–101
.25.
Yang
H
, Liu
C
, Zhang
YQ
, Ge
LT
, Chen
J
, Jia
XQ
. Ilexgenin A induces B16-F10 melanoma cell G1/S arrest in vitro and reduces tumor growth in vivo
. Int Immunopharmacol
. 2015
;24
(2
):423
–31
.26.
Xia
Z-S
, Wang
L
, Yu
T
, Zhong
W
, Lian
G-D
, Wu
D
. MiR-5000-3p, miR-5009-3P and miR-552: potential microRNA biomarkers of side population cells in colon cancer
. Oncol Rep
. 2014
;32
(2
):589
–96
.27.
Wang
N
, Liu
W
. Increased expression of miR-552 acts as a potential predictor biomarker for poor prognosis of colorectal cancer
. Eur Rev Med Pharmacol Sci
. 2018
;22
(2
):412
–6
.28.
Feng
X
, Zhu
M
, Liao
B
, Tian
T
, Li
M
, Wang
Z
. Upregulation of miR-552 predicts unfavorable prognosis of gastric cancer and promotes the proliferation, migration, and invasion of gastric cancer cells
. Oncol Res Treat
. 2020
;43
(3
):103
–11
.29.
Qu
W
, Wen
X
, Su
K
, Gou
W
. MiR‐552 promotes the proliferation, migration and EMT of hepatocellular carcinoma cells by inhibiting AJAP 1 expression
. J Cell Mol Med
. 2019
;23
(2
):1541
–52
.30.
Cai
W
, Xu
Y
, Yin
J
, Zuo
W
, Su
Z
. miR-552-5p facilitates osteosarcoma cell proliferation and metastasis by targeting WIF1
. Exp Ther Med
. 2019
;17
(5
):3781
–8
.31.
Thind
A
, Wilson
C
. Exosomal miRNAs as cancer biomarkers and therapeutic targets
. J Extracell Vesicles
. 2016
;5
(1
):31292
.32.
Makler
A
, Asghar
W
. Exosomal biomarkers for cancer diagnosis and patient monitoring
. Expert Rev Mol Diagn
. 2020
;20
(4
):387
–400
.33.
Zuo
J
, Wen
J
, Lei
M
, Wen
M
, Li
S
, Lv
X
. Hypoxia promotes the invasion and metastasis of laryngeal cancer cells via EMT
. Med Oncol
. 2016
;33
(2
):15
–9
.34.
Brabletz
T
, Kalluri
R
, Nieto
MA
, Weinberg
RA
. EMT in cancer
. Nat Rev Cancer
. 2018
;18
(2
):128
–34
.35.
Zhu
L
, Zhang
S
, Chen
S
, Wu
H
, Jiang
M
, Liu
A
. Exosomal miR-552-5p promotes tumorigenesis and disease progression via the PTEN/TOB1 axis in gastric cancer
. J Cancer
. 2022
;13
(3
):890
–905
.© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.
